Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, comments on the presence of a BRCA mutation in her patients.
Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, comments on the presence of a BRCA mutation in her patients.
While a BRCA mutation used to be considered a negative prognostic factor in patients with breast cancer, it can now be considered a good thing, Daugherty says. Patients with the BRCA mutation are more amenable to platinum therapy and are eligible for PARP trials. It remains important for nurses and doctors to inform patients about new knowledge concerning BRCA.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More